NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Immunovant, Inc. (IMVT) Stock Analysis

Immunovant, Inc. (IMVT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

IMVT

$28.38

−$0.21 (−0.73%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMVT with… →

IMVT Key Statistics

As of Oct 21, 2026
Trading
Open
$28.97
Previous Close
$28.59
Day's Range
28.05–29.15
52-Week Range
18.51–45.42
Volume
1.49M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.84
Valuation
Market Cap
$5.86B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.82
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$505.61M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
206.55M
1-Year Return
+47.58%
Dividend and dates
Earnings Date
November 9, 2026
Avg Volume
1.32M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, IMVT closed at $28.38, +47.58% over 1 year.

Immunovant, Inc. (IMVT) has a market capitalization of $5.86B.

In fiscal 2025, IMVT reported revenue of $0.00.

IMVT Stock Return by Calendar Year

Immunovant, Inc. (IMVT) return since Jun 2019: what $10,000 became

1 year
$10,000 $14,758
+47.58%
5 years
$10,000 $33,506
+235.06%
Since Jun 2019
$10,000 $28,523
+185.23%

If you had invested $10,000 in Immunovant, Inc. (IMVT) at the close on June 21, 2019, the earliest close on record here, it would have been worth $28,523 at the close on October 21, 2026: +185.23% in total, +15.36% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+11.64%
2025+2.62%
2024−41.21%
2023+137.35%
2022+108.33%
2021−81.55%
2020+191.05%
2019 (partial year)+59.50%

As of October 21, 2026.

IMVT Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$505.61M—
2024$0.00−$413.84M—
2023$0.00−$259.34M—
2022$0.00−$210.96M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$532.90M−$505.61M—
2024$0.00—−$438.15M−$413.84M—
2023$0.00—−$270.21M−$259.34M—
2022$0.00—−$208.28M−$210.96M—

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Immunovant, Inc. (IMVT) at $5.86B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 315 employees.

The 52-week range on file runs from $18.51 to $45.42. The most recent close on file for IMVT is $28.38, dated October 21, 2026. That is −$0.21 (−0.73%) against the previous close. The latest close sits 53.32% above that 52-week low.

Financial Health

In fiscal 2025, Immunovant, Inc. reported revenue of $0.00. The same year closed with a net loss of $505.61M. Earnings per share on a trailing basis come to −2.82.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the total return is +47.58%. Measured over 5 years, that is +27.36% a year compounded. The reported beta is 0.84. Annualized volatility over the trailing 7 years is 76.3%.

Growth & Income

The record shows no dividend for IMVT.

2026 is still running; the total return is +11.64% year to date. Across the complete calendar years on file, 2020 returned +191.05% and 2021 returned −81.55%. Of the 6 complete calendar years on file, 4 finished higher.

Peer Comparison

Immunovant, Inc. (IMVT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Immunovant, Inc. IMVT $5.86B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Immunovant, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Immunovant, Inc.

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Visit website →